CA
CRL icon

Calton & Associates’s Charles River Laboratories CRL Stock Holding History

Calton & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-71
Closed -$7K – 516
2017
Q4 		$7K Buy
+71
New +$7.73K ﹤0.01% 1157

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Calton & Associates's CRL Position: Q1 2018 in Review

Calton & Associates sold out of Charles River Laboratories (CRL) in Q1 2018, closing a stake of 71 shares — an estimated $7K sold.

Calton & Associates first reported a position in CRL in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 333 funds tracked by Wall St. Rank hold CRL as of Q1 2018.

  • Calton & Associates reported no remaining Charles River Laboratories position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 71 Charles River Laboratories shares in Q1 2018, an estimated $7K.
  • Calton & Associates first reported a position in Charles River Laboratories in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Charles River Laboratories position peaked at $7K in Q4 2017.
  • 333 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.